Publication | Closed Access

Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma

Tumor BiologyTgf-β ResponsesMedicineLiver PhysiologyCancer Cell BiologyCaveolae/lipid Raft-mediated Internalization/degradationFibroblast Growth FactorPharmacologyRadiation OncologyHepatocellular CarcinomaCancer ResearchCancer GrowthHealth Sciences